EP2417104A1

EP2417104A1 - Sulphurated derivatives of resorcinol, preparation of same and cosmetic uses thereof

Info

Publication number: EP2417104A1
Application number: EP10713194A
Authority: EP
Inventors: Stéphane POIGNY
Original assignee: Pierre Fabre Dermo Cosmetique SA
Current assignee: Pierre Fabre Dermo Cosmetique SA
Priority date: 2009-04-08
Filing date: 2010-04-08
Publication date: 2012-02-15
Also published as: US8859819B2; US20120034176A1; UA109770C2; CN102421751B; AU2010233687A1; JP5612074B2; HK1169377A1; BRPI1016084A2; ZA201107275B; CN102421751A; RU2539589C2; TWI528979B; AR078218A1; RU2011141743A; KR101728178B1; IL215601A; AU2010233687B2; FR2944281B1; GEP20156360B; MA33175B1

Abstract

The present invention relates to a compound of the general formula (I) where: X = S, SO or SO2; and one of the radicals R1 and R2 is a hydrogen atom and the other is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); or a COR3 or CONHR3, but not simultaneously, where R3 is a radical: a C1 to C18 linear or branched alkyl, optionally substituted by one or more halogen atom(s); a C2 to C18 linear or branched alkenyl, optionally substituted by one or more halogen atom(s); an aralkyl, optionally substituted by one or more C1 to C6 alkoxy group(s); an aralkenyl, optionally substituted by one or more C1 to C6 alkoxy groups and/or one or more OH group(s); or an aryl radical, optionally substituted by one or more C1 to C6 alkoxy group(s).

Description

RESORCINOL SULFUR DERIVATIVES, THEIR PREPARATION AND THEIR COSMETIC USES

The present invention relates to novel analogues of resorcinol sulfide, resorcinol sulfoxide and resorcinol sulfone corresponding to general formula (I):

(i) wherein: X = S, SO or SO _2, and; one of the radicals R 1 and R ₂ represents a hydrogen atom and the other a radical:

linear or branched C1 to C18 alkyl optionally substituted by one or more halogen atom (s),

C ₂ -C 18 linear or branched alkenyl, in particular an allyl group, or a 3,3 dimethylallyl group, or a geranyl group or a farnesyl group, optionally substituted with one or more halogen atoms,

an aralkyl, in particular benzyl, optionally substituted with one or more C ₁ -C ₆ alkoxy groups, or

* COR ₃ or CONHR ₃ , but not simultaneously, where R ₃ represents a radical:

> Alk) _'I Uneaire or branched Ci to C ₁₈ optionally substituted by one or more atom (s) halogen, s> dlkemle hrséajre seen ranπfie C ₂ -C ₁₈ optionally substituted by one or more atom (s) halogen, in particular aryl alcohol, optionally substituted by one or more C ₁ -C ₆ alkoxy groups, aralkenyl optionally substituted with one or more C 1 -C alkoxy groups; ₆ and / or OH group (s), or a radical Ic, in particular pherr> ovcntudlcment substituted with one or more group (e) alkoxy Ci-C ₆ . The term "alkyl" represents saturated linear or branched aliphatic hydrocarbon chains and including the specified number of carbon atoms.

The term "alkenyl" represents unsaturated linear or branched aliphatic hydrocarbon chains and including the number of carbon atoms specified for example an allyl group or a 3,3-dimethylallyl group or a geranyl group or a farnesyl group.

The term "alkoxy" represents a linear or branched hydrocarbon chain comprising the specified number of carbon atoms and an oxygen atom, for example a methoxy group, or an ethoxy group, or a propoxy group or a butoxy group.

The term "aryl" represents any monocyclic or bicyclic aromatic carbon ring, such as, for example, phenyl or naphthyl.

The term "aralkyl" refers to an aryl bonded by an alkyl, for example a benzyl, ethylphenyl, propylphenyl. The term "aralkenyl" refers to aryl bonded with alkenyl, for example phenyl acrylate or (4-methoxyphenyl) acrylate or (3, A-dimethoxyphenyl) acrylate.

The term "halogen" represents a fluorine, chlorine, bromine or iodine.

The term "oleoyl" represents the univalent radical derived from oleic acid by the loss of the OH group.

The term "linoleoyl" represents the univalent radical derived from linoleic acid by the loss of the OH group.

The term "alpha-linolenoyl" represents the univalent radical derived from alpha-linolenic acid by the loss of the OH group. The term "gamma-linolenoyl" represents the univalent radical derived from gamma-linolenic acid by the loss of the OH group.

The term "coumaroyl" represents 4-hydroxycinnamoyl.

The term "caffeoyl" represents 3,4-dihydroxycinnamoyl.

The term "feruoyl" represents 4-hydroxy-3-methoxycinnamoyl. The term "sinapoyl" represents 4-hydroxy-3,5-dimethoxycinnamoyl. Among the compounds of general formula (I) forming part of the present invention, a particularly preferred class of compounds corresponds to the compounds of general formula (I) in which X = S. In the same way, the present invention particularly relates to the compounds of general formula (I) in which X = S and R ₂ = H.

Preferably, the compounds according to the invention correspond to the compounds of formula (I) in which X = S, R ₂ = H and R 1 is selected from the group consisting of: linear or branched Ci to Ci alkyl or a linear or branched alkenyl, C ₂ to C ₈ or COR ₃ and CONHR _3. According to one embodiment of the present invention, the compounds of general formula (I) are those for which R 1 represents:

linear or branched C1 to Cs and in particular C4 to Cs alkyl; or

a linear or branched C ₂ -C 18 alkenyl selected from an allyl group or a 3,3-dimethylallyl group or a geranyl group or a farnesyl group; or - a benzyl.

According to the invention, a particularly preferred class of compounds of general formula (I) corresponds to the compounds for which R ₃ represents:

linear or branched C ₇ to C 15 and in particular C ₁ to C 15 alkyl; or

linear or branched C ₁₀ -C ₁₈ alkenyl; or . benzyl; or

an aralkenyl chosen from phenyl acrylate or (4-methoxyphenyl) acrylate or (3,4-dimethoxyphenyl) acrylate; or

a phenyl.

According to a particular embodiment of the invention, the compounds of general formula (I) are those in which COR ₃ represents

an oleoyl or a linoleoyl or an alpha-linolenoyl or a gamma-linolenoyl.

According to another particular embodiment of the invention, the compounds of formula (I) are those for which COR3 represents:

a cinnamoyl substituted with one or more C ₁ -C ₆ alkoxy group (s) and / or OH group (s) chosen from coumaroyl or 4-methoxycinnamoyl or 3,4-dimethoxycinnamoyl or caffeoyl or feruoyl or sinapoyle. According to one embodiment of the invention, the compounds of formula are generally chosen from the following compounds:

4- (4-hydroxy-2 - ((2E, 6E) -3,6, 11-trimethyldodeca-2,6,10-trienyloxy) phenylthio) benzene-1,3-diol,

4- (4-hydroxy-2- (3-methylbut-2-enyloxy) phenylthio) benzene-1,3-diol, (E) -4- (2- (3,7-dimethylocta-2,6-dienyloxy)) 4-hydroxyphenylthio) benzene-1,3-diol, 4- (2-butoxy-4-hydroxyphenylthio) benzene-1,3-diol, -4- (4-butoxy-2-hydroxyphenylthio) benzene-1,3- diol,

4- (4-hydroxy-2- (octyloxy) phenylthio) benzene-1,3-diol, 4- (2-hydroxy-4- (octyloxy) phenylthio) benzene-1,3-diol, 4- (2- ( benzyloxy) -4-hydroxyphenylthio) benzene-1,3-diol, 4- (4- (benzyloxy) -2-hydroxyphenylthio) benzene-1,3-diol, -4- (4-hydroxy-2- (4-methoxybenzyloxy) ) phenylthio) benzene-1,3-diol,

4- (2- (decyloxy) -4-hydroxyphenylthio) benzene-1,3-diol, 4- (2- (hexadecyloxy) -4-hydroxyphenylthio) benzene-1,3-diol, 2- (2,4-dihydroxyphenylthio) -4- dihydroxyphenylthio) -5-hydroxyphenyl dodecanoate, 2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl palmitate, -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octanoate,

4- (2,4-dihydroxyphenylthio) -3-hydroxyphenyloctanoate, 2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3-phenylpropanoate,

4- (2,4-Dihydroxyphenylthio) -3-hydroxyphenyl-3-phenylpropanoate, 2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3-methylbutanoate, -4- (2,4-dihydroxyphenylthio) -3-hydroxyphenyl -méthylbutanoate,

(9Z, 12Z) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octadec-9,12-dienoate

(E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3- (4-methoxyphenyl) acrylate, - (E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl 3 - (3,4) dimethoxyphenyl) acrylate,

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octylcarbamate, 2- (2,4-dihydroxyphenylsulfmyl) -5-hydroxyphenyl dodecanoate,

(9Z, 12Z) -2- (2,4-dihydroxyphenylsulfinyl) -5-hydroxyphenyl octadeca-9,12-dienoate

4- (2- (decyloxy) -4-hydroxyphenylsulfinyl) benzene-1,3-diol, 4- (2- (decyloxy) -4-hydroxyphenylsulfonyl) benzene-1,3-diol. The invention also relates to the use of cosmetic compounds of formula (V), which comprise, in addition to new analogues of formula (I), resorcinol sulfide, resorcinol sulfoxide and resorcinol sulfone, and in particular their use for depigmentation of the skin, for the purpose of implementation of a method of cosmetic treatment of skin aging. General formula (V):

(I ') in which the radicals X, Ri and R ₂ have identical meanings to those given in relation to the formula (I), but where R 1 and R ₂ may also simultaneously represent a hydrogen atom.

The present invention relates to the cosmetic use of the compounds of general formula (F) or formula (I) as an antioxidant active ingredient or as depigmenting active ingredient. The present invention also relates to the use of the compounds of general formula (I) as a drug and in particular as an antibacterial active ingredient.

The invention also relates to pharmaceutical or cosmetic compositions comprising at least one of the compounds of formula (I) or of formula (V) in combination with at least one pharmaceutically or cosmetically acceptable excipient.

In the present invention, the term "pharmaceutically or cosmetically acceptable" is intended to mean that which is useful in the preparation of a pharmaceutical or cosmetic composition, which is generally safe, non-toxic and biologically logically or otherwise undesirable and which is acceptable for therapeutic or cosmetic use, especially by topical application.

The object of the invention relates to a cosmetic composition characterized in that the amount of compound of formula (I) or of formula (T) varies between 0.01% and 10% and preferably from 0.1% to 5% by weight relative to the total weight of the composition.

The present invention relates to a method for bleaching and / or lightening human skin and / or hair and / or hair comprising applying to the skin and / or the hairs and / or the hair of a cosmetic composition containing at least one compound of formula (I) or formula (T). The present invention relates to a method for the treatment and / or cosmetic prevention of aging of the skin, comprising the application to the skin of a cosmetic composition containing at least one compound of formula (I) or of formula

(T)

The subject of the invention also extends to the process for synthesizing the new compounds of formula (I).

According to another characteristic of the present invention, this also relates to a process for preparing a compound of general formula (I), characterized in that 4,4'-thiodibenzene-1,3-diol is reacted. or 4,4'-sulfinylbis-1,3-benzenediol with a halide of formula II:

HaI - Ri (II)

in which :

HaI represents a halogen atom, and R 1 has the same meaning as that given previously with regard to formula (I) with the exception of a hydrogen atom.

According to another characteristic of the present invention, this also relates to a process for preparing a resorcinol derivative of formula (I) in which X represents SO or SO ₂ , characterized in that a compound of formula (I) wherein X represents a sulfur atom, in particular using an aqueous solution of hydrogen peroxide.

The present invention will be better understood with reference to the examples given below by way of illustration only. I. Synthesis of the compounds of the invention.

1) Synthesis of analogues of resorcinol sulfide.

- Example 1 (resorcinol sulphide):

- 4,4'-thiodibenzene-1,3-diol

¹ R NMR (400 MHz, DMSO-d6): δ: 6.19 (dd, 2H); 6.34 (d, 2H); 6.87 (d, 2H); 9.41 (brs, 2H); 9.50 (s wide, 2H).

¹³ C NMR (100 MHz, DMSO d6): δ: 102.58; 107.52; 111.46; 133.90; 157.04; 158.37.

MS (ESI-): 249.1 [MH] ^-

A) Synthesis of ethers: Synthesis of ethers by coupling resorcinol sulfide with an alkyl halide

To a suspension of 4,4'-thiodibenzene-1,3-diol (resorcinol sulfide, 3g,

12 mmol, 4 eq.) And potassium carbonate (497 mg, 3.6 mmol, 1.2 eq.) In 20 ml of anhydrous DMF (= dimethylformamide) and under nitrogen are added 856 mg of farnesyl bromide ( 3 mmol, 1 eq.) And the mixture is stirred at 80 ^° C. for 6 hours. The reaction is monitored by TLC (= thin layer chromatography).

After cooling to room temperature, the solvent is evaporated and the residue is extracted with a mixture of ethyl acetate / water. The organic phase is washed twice with water and then with a saturated solution of NaCl. After drying over magnesium sulfate, a solid is obtained after evaporation of the solvent. The solid is washed with DCM (= dichloromethane) and then collected to provide 2 g of unreacted starting resorcinol sulfide.

The filtrate (DCM) is then evaporated to yield an oil purified on silica with the heptane / ethyl acetate mixture (95/5 to 50/50) or by preparative HPLC. The product obtained as a colorless oil is dried under vacuum overnight. 730 mg are then obtained with a yield of 55%.

The structure is determined by proton NMR, carbon, HMBC, HMQC and NOESY analyzes. -Example 2:

4- (4-Hydroxy-2 - ((2E, 6E) -3,6,11-trimethyldodeca-2,6,10-trienyloxy) phenylthio) benzene

-1,3-diol

¹ U NMR (500 MHz, CDCl ₃ ): δ: 1.58 (s, 3H); 1.60 (s, 3H); 1.66 (s, 3H); 1.73 (s, 3H); 1.96 (m, 2H); 2.04 (m, 2H); 2.09 (m, 2H); 2.14 (m, 2H); 4.56 (d, j = 6.4 Hz, 2H); 5.01 (s, 1H, OH para S); 5.06 (s, 1H, OH para S); 5.07 (m, 1H); 5.11 (m, 1H); 5.51 (t, 1H); 6.29 (d, j = 8.5-2.4 Hz, 1H); 6.32 (d, J = 8.2-2.7 Hz, 1H); 6.38 (d, j = 2.4 Hz, 1H); 6.42 (d, J = 2.7 Hz, 1H); 7.08 (d, j = 8.5 Hz, 1H); 7.33 (s, 1H, OH, ortho S); 7.38 (d, j = 8.5 Hz, 1H).

¹³ C NMR (125 MHz, CDCl ₃ ): δ: 16.04; 16.75; 17.69; 25.70; 26.20; 26.70; 39.54; 39.66; 65.99; 100.68; 102.31; 108.18; 108.33; 110.79; 115.32; 118.49; 123.62; 124.34; 131.38; 133.99; 135.50; 137.54; 142.24; 156.88; 158.09; 158.48; 158.73.

MS (APCI): 455.2 [M + H] ⁺ Rf (1/1; Heptane / EtOAc): 0.75

-Example 3:

4- (4-hydroxy-2- (3-methylbut-2-enyloxy) phenylthio) benzene-1,3-diol

From 1-Bromo-3-methylbut-2-ene (= alkyl halide)

H

¹ H NMR (400 MHz, CDCl ₃ ): δ: 1.76 (s, 3H); 1.82 (s, 3H); 4.56 (d, 2H); 5.07 (m, 2H, 2xOH para S); 5.53 (t, 1H); 6.30 - 6.45 (m, 4H); 7.09 (d, 1H); 7.32 (s, 1H); 7.40 (d, 1H).

MS (APCI +): 319.0 [M + H] ⁺

- Example 4:

- (E) -4- (2- (3,7-Dimethylocta-2,6-dienyloxy) -4-hydroxyphenylthio) benzene-1,3-diol From Geranyl Chloride

¹ R NMR (400 MHz, CDCl ₃ ): δ: 1.62 (s, 3H); 1.68 (s, 3H); 1.75 (s, 3H); 2.13 (m, 2H); 4.59 (d, 2H); 4.80 (s, 1H); 4.85 (s, 1H); 5.11 (s, 1H); 5.53 (t, 1H); 6.30 - 6.45 (m, 4H); 7.09 (d, 1H); 7.32 (s, 1H); 7.41 (d, 1H).

MS (APCI +): 386.9 [M + H] ⁺

Example 5: 4- (2-Butoxy-4-hydroxyphenylthio) benzene-1,3-diol

From 1-bromo-butane. Majority product (590 mg)

¹ R NMR (400 MHz, CDCl ₃ ): δ: 1.01 (t, 3H); 1.53 (m, 2H); 1.88 (m, 2H); 4.02 (t, 2H); 4.78 (bs, 2H, 2 OH para S); 6.32 (m, 2H); 6.36 (s, 1H); 6.45 (s, 1H); 7.08 (d, 1H); 7.29 (s, 1H, OH, ortho S); 7.40 (d, 1H).

MS (APCI +): 307.0 [M + H] ⁺

- Example 6:

4- (4-Butoxy-2-hydroxyphenylthio) benzene-1,3-diol

From 1-bromo-butane. Minority product (18 mg)

¹ U NMR (400 MHz, CDCl ₃ ): δ: 1.02 (t, 3H); 1.44 (m, 2H); 1.72 (m, 2H); 3.90 (t, 2H); 6.34 (d, 1H); 6.41 (d, 1H); 6.43 (s, 1H); 6.49 (s, 1H); 7.25 (m, 3H).

MS (APCI +): 307.1 [M + H] ⁺

Example 7

4- (4-hydroxy-2- (octyloxy) phenylthio) benzene-1,3-diol from 1-bromooctane. Majority product (1.3 g)

¹ R NMR (400 MHz, CDCl ₃ ): δ: 0.91 (t, 3H); 1.30 (m, 8H); 1.47 (m, 2H); 1.88 (m, 2H); 3.99 (t, 2H); 4.90 (bs, 2H); 6.30 (d, 1H); 6.35 (d, 1H); 6.36 (s, 1H); 6.45 (s, 1H); 7.07 (d, 1H); 7.32 (brs, 1H); 7.41 (d, 1H).

MS (APCI +): 363.2 [M + H] + - Example 8:

4- (2-hydroxy-4- (octyloxy) phenylthio) benzene-1,3-diol from 1-bromooctane. Minority product (100 mg)

¹ R NMR (400 MHz, CDCl ₃ ): δ: 0.87 (t, 3H); 1.27 (m, 8H); 1.41 (m, 2H); 1.72 (m, 2H); 3.90 (t, 2H); 6.34 (d, 1H); 6.41 (d, 1H); 6.44 (s, 1H); 6.48 (s, 1H); 7.25 (m, 3H) MS (APCI +): 363.1 [M + H] ⁺

-Example 9:

4- (2- (benzyloxy) -4-hydroxyphenylthio) benzene-1,3-diol

From benzyl bromide. Majority product (600 mg)

¹ U NMR (400 MHz, CDCl ₃ ): δ: 4.80 (broad m, 2H); 5.14 (s, 2H); 6.34 (m, 2H); 6.44 (s, 2H); 7.02 (d, 1H); 7.08 (s, 1H); 7.34-7.41 (m, 6H).

MS (APCI +): 341.1 [M + H] ⁺ Example 10

4- (4- (benzyloxy) -2-hydroxyphenylthio) benzene-1,3-diol From benzyl bromide. Minority product (28 mg)

¹ U NMR (400 MHz, CDCl ₃ ): δ: 5.00 (s, 2H); 6.34 - 6.57 (m, 4H); 7.28 - 7.39 (m, 7H).

MS (APCI +): 341.1 [M + H] ⁺

- Example 11:

4- (4-hydroxy-2- (4-methoxybenzyloxy) phenylthio) benzene-1,3-diol

From 4-methoxybenzyl bromide. Majority product (600 mg)

¹ H NMR (400 MHz, CDCl ₃ ): δ: 3.82 (s, 3H); 5.04 (s, 2H); 5.24 (broad m, 2H); 6.34 (m, 2H); 6.44 (m, 2H); 6.92 (d, 2H); 7.03 (d, 1H); 7.14 (brs, 1H); 7.37 (m, 3H). MS (APCI +): 371.0 [M + H] ⁺ - Example 12:

4- (2- (Decyloxy) -4-hydroxyphenylthio) benzene-1,3-diol

Procedure of Example 2 but with 2 equivalents of resorcinol sulfide, 1 equivalent of 1-Iododecane 16 hours at room temperature.

The product is obtained in the form of a white solid after purification with a yield of 83%.

¹ U NMR (400 MHz, CDCl ₃ ): δ: 0.91 (t, 3H); 1.25 (m, 12H); 1.47 (m, 2H); 1.88 (m, 2H); 3.99 (t, 2H); 4.90 (bs, 2H); 6.30 (d, 1H); 6.35 (d, 1H); 6.36 (s, 1H); 6.45 (s, 1H); 7.07 (d, 1H); 7.32 (brs, 1H); 7.41 (d, 1H).

¹³ C NMR (100 MHz, DMSO): δ: 13.89; 22.04; 25.39; 28.56; 28.65; 28.70; 28.89; 28.94; 31.24; 67.76; 100.18; 102.66; 107.47; 107.62; 107.98; 113.65; 130.42; 135.21; 156,83; 157.34; 158.20; 158.81MS (APCI +): 391.1 [M + H] ⁺

Example 13

4- (2- (hexadecyloxy) -4-hydroxyphenylthio) benzene-1,3-diol Same synthesis as SP02-131 from 1-Iodo-hexadecane

Product obtained in the form of a white solid with a yield of 84%.

¹ R NMR (400 MHz, CDCl ₃ ): δ: 0.88 (t, 3H); 1.2 (m, 24H); 1.47 (m, 2H); 1.84 (m, 2H); 3.92 (t, 2H); 5.31 (brs, 2H); 6.27 (dd, 1H); 6.33 (s, 1H); 6.36 (d, 1H); 6.45 (s, 1H); 7.05 (d, 1H); 7.38 (bs, 1H); 7.41 (d, 1H). ¹³ C NMR (100 MHz, CDCl ₃ ): δ: 14.11; 22.68; 25.95; 28.89; 29.35; 29.56; 29.61; 29.66; 29.70; 31.91; 69.22; 100.39; 102.29; 108.19; 108.54; 110.89; 115.01; 133.93; 137.49; 156.88; 158.19; 158.40; 158.44. MS (ESI-): 473.2 [MH]

B) Synthesis of Esters a) Route 1: Coupling from Resorcinol Sulfide

To a solution of 4,4'-thiodibenzene-1,3-diol (resorcinol sulfide, Ig, 4 mmol, 4 eq.) And triethylamine (177 μl, 1.2 mmol, 1.2 eq.) In 20 ml. anhydrous THF (tetrahydrofuran) and under nitrogen are added dropwise 219 mg of lauroyl chloride (1 mmol, 1 eq.) and the mixture is stirred at room temperature for 1 hour. The reaction is monitored by TLC.

After cooling to room temperature, the solvent is evaporated and the residue is extracted with a mixture of ethyl acetate / water. The organic phase is washed twice with water and then with a saturated solution of NaCl. After drying over magnesium sulfate, a solid is obtained after evaporation of the solvent. The solid is washed with DCM and then collected to provide 510 mg of unreacted starting resorcinol sulfide.

The filtrate (DCM) is then evaporated to yield a purified oil on silica with the cyclohexane / ethyl acetate mixture (9/1) or by preparative HPLC (high performance liquid chromatography). The product obtained as a colorless oil is dried under vacuum overnight. The product solidifies when cold. 260 mg are then obtained in the form of a white solid with a yield of 60%.

- Example 14:

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl dodecanoate

¹ R NMR (500 MHz, CDCl ₃ ): δ: 0.86 (t, J = 7 Hz, 3H); 1.32 (m, 17H); 1.79 (q, J = 7.6 Hz, 2H); 2.63 (t, J = 7.5 Hz, 2H); 5.30 (s, 1H); 5.35 (s, 1H); 6.38 (dd, J = 8.4 and 2.6 Hz, 1H); 6.45 (d, J = 2.7 Hz, 1H); 6.48 (dd, J = 8.5 and 2.7 Hz, 1H); 6.50 (d, J = 2.4 Hz, 1H); 6.73 (d, J = 8.5 Hz, 1H); 6.76 (s, 1H); 7.35 (d, j = 8.5 Hz, 1H).

¹³ C NMR (125 MHz, CDCl ₃ ): δ: 14.12; 22.67; 24.83; 29.13; 29.22; 29.32; 29.44; 29.59; 31.89; 34.24; 103.01; 107.84; 108.72; 110.12; 114.67; 120.06; 130.45; 137.96; 148.93; 155.48; 158.48; 159.03; 172.98. MS (APCI): 433.1 [M + H] ⁺ Rf (7/3; Heptane / EtO Ac): 0.58

-Example 15:

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octanoate

From octanoyl chloride

¹ U NMR (400 MHz, CDCl ₃ ): δ: 0.82 (t, 3H); 1.29 (m, 8H); 1.63 (m, 2H); 2.35 (t, 2H); 6.41 (d, 1H); 6.49 (s, 1H); 6.56 (s, 1H); 6.57 (d, 1H); 6.81 (d, 1H); 7.39 (d, 1H).

MS (APCI +): 377.1 [M + H] ⁺

Example 16: 4- (2,4-Dihydroxyphenylthio) -3-hydroxyphenyl octanoate From Octanoyl Chloride

¹ R NMR (400 MHz, CDCl ₃ ): δ: 0.88 (t, 3H); 1.33 (m, 8H); 1.72 (m, 2H); 2.53 (t, 2H); 6.36 (d, 1H); 6.41 (s, 1H); 6.58 (d, 1H); 6.71 (s, 1H); 7.31 (m, 2H). MS (APCI +): 377.1 [M + H] ⁺

Example 17

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3-phenylpropanoate from hydro-cinnamoyl chloride

¹ H NMR (400 MHz, CDCl ₃ ): δ: 2.98 (t syst AB, 2H); 3.13 (t syst AB, 2H); 5.40 (bs, 2H); 6.41 (d, 1H); 6.46 (s, 1H); 6.48 (s, 1H); 6.54 (d, 1H); 6.79 (d, 1H); 7.22 - 7.38 (m, 6H).

MS (APCI +): 383.1 [M + H] ⁺

- Example 18:

4- (2,4-dihydroxyphenylthio) -3-hydroxyphenyl-3-phenylpropanoate from hydro-cinnamoyl chloride

¹ U NMR (400 MHz, CDCl ₃ ): δ: 2.86 (t syst AB, 2H); 3.04 (t syst AB, 2H); 6.36 (d, 1H); 6.42 (s, 1H); 6.50 (d, 1H); 6.61 (s, 1H); 7.22 - 7.38 (m, 7H). MS (APCI +): 383.1 [M + H] ⁺

- Example 19:

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3-methylbutanoate from isovaleroyl chloride

¹ H NMR (400 MHz, CDCl ₃ ): δ: 1.10 (d, 6H); 2.31 (m, 1H); 2.53 (d, 2H); 4.79 (bs, 1H); 4.87 (brs, 1H); 6.42 (d, 1H); 6.49 (s, 1H); 6.56 (s, 1H); 6.58 (d, 1H); 6.76 (s, 1H); 6.82 (d, 1H); 7.40 (d, 1H). MS (APCI +): 335.0 [M + H] ⁺

Example 20

4- (2,4-dihydroxyphenylthio) -3-hydroxyphenyl-3-methylbutanoate from isovaleroyl chloride

¹ R NMR (400 MHz, CDCl ₃ ): δ: 1.03 (d, 6H); 2.22 (m, 1H); 2.40 (d, 2H); 4.75 (bs, 2H); 6.38 (d, 1H); 6.46 (s, 1H); 6.57 (d, 1H); 6.69 (s, 1H); 7.30 (m, 3H). MS (APCI +): 335.1 [M + H] ⁺

Example 21

- (9Z, 12Z) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octadeca-9, 12-dienoate From linoleoyl chloride

¹ H NMR (400 MHz, CDCl ₃ ): δ: 0.88 (t, 3H); 1.32 (m, 14H); 1.80 (m, 2H); 2.04 (m,

4H); 2.63 (t, 2H); 2.79 (t, 2H); 5.35 (m, 4H); 6.38 (d, 1H); 6.45 (s, 1H); 6.51 (m,

2H); 6.73 (d, 1H); 7.35 (d, 1H).

MS (ESI): 513.2 [M + H] ⁺

Rf (1/1; Heptane / EtOAc): 0.75

b) Route 2: Coupling via Carbodiimide

To a solution of N- (3-Dimethylaminopropyl) -N'-ethylcarbodiimide hydrochloride (960 mg, 5 mmol) and 4-DMAP (4-dimethylaminopyridine) (0.5 mmol) in 20 ml of anhydrous DMF under N 2 are added. 620 mg of A-acid

Methoxycinnamic (3.5 mmol) then the mixture is stirred for 15 minutes. 3.5 g of 4,4'-thiodibenzene-1,3-diol (resorcinol sulphide, 14 mmol, 4 eq.) Are added and the mixture is stirred at room temperature for 4 days.

The solvent is evaporated and then the residue purified on silica CHCl ₃ / MeOH (95/5) to provide 320 mg of pure product in the form of a white solid after evaporation and drying in a vacuum oven.

Yield: 22% Example 22

- (E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3- (4-methoxyphenyl) acrylate

¹ R NMR (400 MHz, CDCl ₃ ): δ: 3.86 (s, 3H); 5.00 (bs, 1H); 5.07 (brs, 1H); 6.40 (dd, 1H); 6.48 (d, 1H); 6.60 (m, 2H); 6.64 (d, 1H); 6.85 (d, 1H); 6.95 (d, 2H); 7.40 (d, 1H); 7.58 (d, 2H); 7.91 (d, 1H). MS (APCI +): 411.0 [M + H] ⁺ Rf (1/1; Heptane / EtOAc): 0.14

Example 23

- (E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl 3- (3,4-dimethoxyphenyl) acrylate From 3,4-Dimethoxycinnamic acid

¹ U NMR (400 MHz, DMSO-d6): δ: 3.82 (s, 3H); 3.84 (s, 3H); 6.22 (d, 1H); 6.37 (d, 1H); 6.61 (s, 1H); 6.64 (d, 1H); 6.77 (d, 1H); 6.92 (m, 2H); 7.01 (d, 1H); 7.31 (d, 1H); 7.43 (s, 1H); 7.72 (d, 1H); 9.58 (m, 2H); 9.78 (m, 1H). MS (ESI +): 441.0 [M + H] ⁺ Rf (95/5, DCM / MeOH): 0.66 C. Synthesis of carbamates

To a solution of 4,4'-thiodibenzene-1,3-diol (resorcinol sulfide, 5 g, 20 mmol, 4 eq) in 40 ml of anhydrous THF and under nitrogen, 0.88 ml of toluene are added dropwise. octyl isocyanate (5 mmol, 1 eq.) and the mixture is stirred for 9 hours under reflux. The reaction is monitored by TLC.

After cooling to room temperature, the solvent is evaporated and the residue is extracted with a mixture of ethyl acetate / water. The organic phase is washed twice with water and then with a saturated solution of NaCl. After drying over magnesium sulfate, a solid is obtained after evaporation of the solvent. The solid is washed with DCM and then collected to provide unreacted starting resorcinol sulfide.

The filtrate (DCM) is then evaporated to yield an oil purified on silica with the cyclohexane / ethyl acetate mixture or preparative HPLC. The product obtained as a colorless oil is dried under vacuum overnight. 540 mg are then obtained in the form of a colorless oil with a yield of 27%.

- Example 24:

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octylcarbamate

¹ R NMR (400 MHz, CDCl ₃ ): δ: 0.86 (t, 3H); 1.26 (m, 8H); 1.35 (m, 2H); 1.59 (m,

2H); 3.32 (m, 2H); 5.30 (t, 1H); 5.93 (brs, 1H); 6.23 (brs, 1H); 6.35 (m, 2H);

6.41 (s, 1H); 6.52 (s, 1H); 6.63 (d, 1H); 7.32 (brs, 1H); 7.35 (d, 1H).

MS (ESI +): 406.1 [M + H] ⁺ 2) Synthesis of resorcinol sulfoxide analogues

Example 25 (Resorcinol Sulfoxide)

4,4'-sulfinyldibenzene-1,3-diol

¹ H NMR (400 MHz, DMSO-d6): δ: 6.32 (m, 4H); 7.10 (d, 2H); 9.82 (bs, 2H); 10.13 (broad s, 2H).

MS (APCI): 267.0 [M + H] ⁺

A) Synthesis of the esters

A suspension of 4,4'-sulphinylbis-1,3-benzenediol (resorcinol sulphoxide, 2.66 g, 10 mmol, 4 eq.) In 100 ml of anhydrous THF is solubilized under heat and under nitrogen, and is then added after 5 minutes to room temperature, 420 μl of triethylamine (12 mmol, 1.2 eq). Rapid precipitation is observed then 547 mg of lauroyl chloride (2.5 mmol, 1 eq) are added dropwise. The mixture is stirred for 2 hours at room temperature. The reaction is monitored by TLC.

After returning to ambient temperature, the solid is filtered and the filtrate is evaporated to yield an oil purified on silica with the heptane / ethyl acetate mixture (80/20 to 50/50) or by preparative HPLC. The product is obtained as a white solid and dried under vacuum overnight. 511 mg are then obtained with a yield of 46%.

Example 26: 2- (2,4-dihydroxyphenylsulfinyl) -5-hydroxyphenyl dodecanoate

¹ H NMR (400 MHz, DMSO-d6): δ: 0.86 (t, 3H); 1.24 (m, 16H); 1.53 (m, 2H); 2.45 (m, 2H); 6.28 (d, 1H); 6.33 (dd, 1H); 6.53 (s, 1H); 6.83 (dd, 1H); 7.12 (d, 1H); 7.43 (d, 1H); 9.88 (si, 1H); 10.19 (si, 1H); 10.27 (si, 1H).

MS (APCI +): 449.2 [M + H] ⁺ Rf (1/1; Heptane / EtOAc): 0.42

Example 27 (9Z, 12Z) -2- (2,4-dihydroxyphenylsulfinyl) -5-hydroxyphenyl octadecanone

9,12-dienoate

From linoleoyl chloride

¹ U NMR (400 MHz, DMSO-d6): δ: 0.84 (t, 3H); 1.29 (m, 14H); 1.55 (m, 2H); 2.00 (m, 4H); 2.42 (t, 2H); 2.76 (t, 2H); 5.33 (m, 4H); 6.28 (s, 1H); 6.35 (ds, 1H); 6.53 (s, 1H); 6.82 (d, 1H); 7.12 (d, 1H); 7.43 (d, 1H); 9.88 (s, 1H); 10.19 (s, 1H); 10.27 (s, 1H).

MS (ESI): 529.2 [M + H] ⁺ Rf (7/3; Heptane / EtOAc): 0.45

B) Synthesis of ethers by oxidation of resorcinol sulfide analogues

To a solution of Example 12 (= 4- (2- (decyloxy) -4-hydroxyphenylthio) benzene-1,3-diol (320 mg) in 10 ml of acetic acid is added 260 μl of a solution. 30% hydrogen peroxide in H ₂ O (2.5 mmol, 3 eq) and the mixture is stirred for 3 hours at room temperature. 50 mL of water is added to precipitate the product. The solid obtained is collected and then taken up in ethyl acetate and this organic phase is washed with water and then with a saturated solution of sodium chloride. After drying over MgSO4, the The solvent is evaporated to yield a beige solid dried overnight in a vacuum oven (50mbar, 50 ⁰ C). 310 mg of product are obtained with a yield of 90%.

Example 28 4- (2- (Decyloxy) -4-hydroxyphenylsulfinyl) benzene-1,3-diol

¹ R NMR (400 MHz, DMSO d6): δ: 0.86 (t, 3H); 1.23 (m, 14H); 1.54 (m, 2H); 3,77-

3.92 (m, 2H); 6.26 (d, 1H); 6.29 (s, 1H); 6.40 (d, 1H); 6.49 (dd, 1H); 6.98 (d, 1H);

6.76 (s, 1H); 7.28 (d, 1H); 9.80 (s, 1H); 9.98 (s, 1H); 10.06 (s, 1H).

¹³ C NMR (100 MHz, DMSO d6): δ: 13.89; 22.03; 25.14; 25.38; 28.29; 28.64; 28.66;

28.90; 28.93; 31.25; 67.86; 99.86; 102.38; 107.12; 107.49; 120.17; 121.72; 127.19;

127.68; 156.82; 157.07; 160.95; 161.18.

MS (ESI +): 407.2 [M + H] ⁺ Rf (1/1; Heptane / EtOAc): 0.12

3) Synthesis of Resorcinol Sulfone Analogs

A) Synthesis of resorcinol sulfone To a solution of 4,4'-thiodibenzene-1,3-diol (resorcinol sulfide, 10 mmol, 2.5 g) in acetone / acetic acid (1/1, 60 ml) is added 5.12 mL of a solution of 30% hydrogen peroxide in H2O (30 mmol) and the mixture is stirred

72 hours at room temperature.

The solvent is evaporated and the solid obtained is taken up in ethyl acetate to obtain a white solid. Filtration of the solid then the filtrate is evaporated and the residue thus obtained is purified on silica to yield 320 mg of a white solid Example 29

4,4'-sulfonyldibenzene-1,3-diol (resorcinol sulfone)

¹ R NMR (400 MHz, DMSO-d6): δ: 6.24 (d, 2H); 6.33 (dd, 2H); 7.61 (d, 2H); 10.06 (s, 1H); 10.16 (s, 1H).

NMR 1 ¹ 3 C ^J (100 MHz, DMSO d6): δ: 102.73; 106.41; 117.98; 131.54; 157.14; 162.86.

Rf (9/1, DCM / MeOH) 0.6

B) Synthesis of Resorcinol Sulfone Analogues by Oxidation of Resorcinol Sulfide Analogs to Resorcinol Sulfone

To a solution of Example 12 (= 4- (2- (decyloxy) -4-hydroxyphenylthio) benzene-1,3-diol (195 mg, 0.5 mmol) in 10 ml of acetic acid are added. 8 mL of a solution of 30% hydrogen peroxide in H ₂ O (25 mmol, 50 eq) and the mixture is stirred for 48 hours at room temperature.

50 mL of water is added to precipitate the product. The solid obtained is collected on fried, then washed twice with water and then twice with n-pentane. The solid is then dried overnight in a vacuum oven (50mbar, 50 ⁰ C) to give a white solid. 135 mg of product are obtained with a yield of 64%.

Example 30

4- (2- (Decyloxy) -4-hydroxyphenylsulfonyl) benzene-1,3-diol

¹ H NMR (400 MHz, DMSO d6): δ: 0.87 (tl, 3H); 1.26 (m, 14H); 1.44 (ml, 2H); 3.77 (ml, 2H); 6.22 (s, 1H); 6.30 (d, 1H); 6.35 (s, 1H); 6.44 (d, 1H); 7.59 (d, 1H); 7.74 (d, 1H); 9.97 (s, 1H); 10.10 (s, 1H); 10.30 (s, 1H).

¹³ C NMR (100 MHz, DMSO d6): δ: 13.89; 22.02; 25.29; 28.25; 28.64; 28.75; 28.88; 28.92; 31.24; 67.96; 99.78; 102.66; 106.04; 106.28; 117.91; 119.88; 131.65; 131.82; 156.97; 157.69; 162.77; 163.15.

II Results of biological tests 1) Protocols

A) Determination of depigmenting activity on acellular in vitro test: tyrosinase inhibition test) - Principle:

This test is used to evaluate the depigmenting activity of the molecules tested. Tyrosinase is a limiting enzyme in melanogenesis.

It belongs to the family of oxidoreductases. It has the particular function: monophenol monooxygenase (MPMO) and polyphenol oxidase (PPO).

It is synthesized at the level of melanocytes. It is activated during its migration to keratinocytes via melanosomes. It transforms tyrosine into DOPA then dopaquinone, which ultimately leads to a polymerization or a production of pigments (see diagram below).

melanin

MPMO PPO

The substrate: L-tyrosine is converted into L-DOPA by the monophenol monooxygenase function which is converted by the tyrosinase function polyphenol oxidase to dopaquinone. The latter will self-oxidation to dopachrome which is measured spectrophotometrically at 490 nm. More precisely, it is the global tyrosinase activity (MPMOg) that is measured since it is the dopachrome in fine that is dosed. Thus the products tested on MPMOg (= measurement of the activity on PPO and MPMO) can accumulate the inhibition of the 2 functions,

inhibit only MPMO stricto sensus function (transformation of tyrosine into DOPA) in addition to the PPO test, could inhibit PPO only

- General experimental conditions:

Reader: Synergy HT program: tyrosinase 280-490 kinetics: kinetics over 45 min, reading at t = 10minutes, Tests in 96 transparent wells, Buffer Phosphate - pH 6.8, Enzyme: mushroom tyrosinase - Sigma = T-3824Substrate: L-Tyrosine - Sigma = T-3754, positive control: kojic acid (AK) - fiuka = 60890 (reference inhibitor)

- Reference molecules for the test:

Kojic Acid: 9μM <50μM IC <20μM (PPO), 3μM <50μm IC <7μM (MPMO)

Vitamin C: 20μM <IC 50 <40μM (PPO)

Glutathione reduced: 55% inhibition at 25 μM (PPO), IC 50 = 1-2 μM (MPMO) Hydroquinone: IC 50 = 3-4 μM (MPMO) Arbutin: 57% inhibition at 88 μM (MPMO)

These exogenous molecules are known to negatively regulate melanogenesis. Hydroquinone inhibits melanin synthesis by presenting itself as a tyrosinase substrate in order to divert its activity. Arbutin containing hydroquinone acts in the same way. Kojic acid decreases the activity of tyrosinase by inhibiting UV-induced hyperpigmentation. Vitamin C would inhibit tyrosinase but also behave as a potent reducer by preventing the staining of melanin by oxidation. Vitamin A decreases the expression of tyrosinase. B) Assay of the melanin assay in B16-F10 cells:

- Principle:

This is a test for measuring melanin synthesis by colorimetric assay on a murine melanoma cell line: the B16-F10 line. This test makes it possible to evaluate the depigmenting power of active principles.

The B 16 -Fl O cells are seeded in 96-well plates in DMEM medium supplemented with FCS (fetal calf serum), and incubated for 24 hours at room temperature.

37 ° C, 5% CO2. The cells are then stimulated with 0.1 μM α-MSH (to stimulate melanin synthesis, the observed stimulation is approximately 150%) and treated for 72 hours with the active agents to be tested. Each concentration of asset is tested at least in triplicate. Total melanin followed by intracellular melanin dissolved in lysis buffer is then assayed by absorbance reading at 405 nm. The total proteins are assayed in the lysate and the results are expressed in mg melanin / mg proteins. The percentage of activity is calculated as follows: Standardized Mean of the Control - Standardized Mean of the Treaty

% of activity = x 100

Standard average of the control

A negative value indicates an inhibition, while a positive value indicates an induction of melanin synthesis.

- General experimental conditions:

- Material:

- CO2 Cell Incubator (Heraeus), Oven, Centrifuge (Heraeus), Laminar Air Flow Hood, 96-well Flat Bottom Plates - Falcon, Sterile Cones - Treff Lab, Polylabo, Mithras LB940 (Berthold Technologies) - 154 / MIP A / 003

- biological material:

- B16-F10 cell line between PlO and P20 (murine melanocytes) (ATCC, CRL-6475) - Reagents:

- DMEM without phenol red (GlBCOBRL, 31053-028), Glutamax-I Supplement at 20OmM (GlBCOBRL, 35050-038), D-PBS (GlBCOBRL, 14190-094), Calf Serum fetal (Invitrogen, 10270-098), Trypsin-EDTA (GlBCOBRL, 25300-054), NaOH (Sigma, S8045-500G), DMSO (Sigma, 471267-1L), Nie, Phe-Melanocyte Stimulating Hormone (Sigma, M- 8764), Melanine (Sigma, M-0418), BCA-COPPER (SlGMA, B9643 and C2284), BSA (SIGMA, P0914)

C) Test for the study of the antioxidant capacity by chemiluminiscence (Photochem analytic Jena) - Principle:

This test is used to determine the antioxidant capacity of molecules. It is a method that generates free radicals by a photochemical signal. The intensity of the oxidation is 1000 times higher than those obtained under normal conditions.

Detection is by chemiluminescence. It allows the evaluation of hydrosoluble and liposo lubies molecules or anti-oxidant extracts.

The results are expressed respectively in equivalent amount of vitamin C or Trolox (6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid). The sensitivity is of the order of the nanomole.

The antioxidant activity studied in this test represents the ability to specifically trap superoxide anions by chemiluminescence.

Quantified results are expressed in Trolox equivalents (standard), ie "μg of product for 1 μg of Trolox". This means that it takes a quantity x of sample to obtain an activity equivalent to the activity detected for 1 μg of standard. It is an antioxidant power relative to a reference, it frees us from the concentration tested.

- Generation of oxygenated free radicals:

The superoxide radical: O ₂ ^"" is generated by a photochemical reaction:

L + hv (UV) + O ₂ > L * O ₂ > L ⁰⁺ + O ₂ ^{° "}

L *: luminol in the excited state L ⁰⁺ : luminol radical - Signal detection:

Part of the superoxide anions is quenched by antioxidants. The remaining free radicals are quantified by chemiluminescence.

L ⁰⁺ + O ₂ ^{° "} > N2 AP * 2- AP ² - hv (luminescence)

AP * ^" : excited aminophthalate

D) Linoleic acid protection test following UV stress.

- Target: protection of linoleic acid in Fenton condition, UV irradiation

Linoleic acid belongs to the family of polyunsaturated fatty acids (PUFAs). Sensitive to oxidation, linoleic acid is a preferred target for free radicals (RLO) in biological media. When biological membranes are exposed to oxidative stress, the most affected components are phospholipids consisting of PUFAs and cholesterol. Their degradation leads to lipid peroxidation and generally to destructuring. Lipid peroxidation is an auto-catalytic process that usually involves RLOs. Lipid peroxidation is partly responsible for skin aging.

The method used to evaluate lipid peroxidation is based on the coupling of thiobarbituric acid (TBA) and by-products of degradation leading to detectable color compounds in spectrofluorometry. The essential secondary compound of final degradation is malondialdehyde, MDA. MDA is a carcinogenic and mutagenic aldehyde, it acts on proteins, and DNA. - Principle of the test:

The test sample is brought into contact with linoleic acid in a weight / weight ratio. The sample is irradiated with 10 DEM (Minimal Erythemal Dose) in Fenton condition, namely in the presence of H 2 O 2 and iron II in a solar simulator.

Following irradiation, the reaction is taken up in methanol and derivatized at 90 ^° C. with TBA. The chromogen, the MDA-TBA complex, representative of the MDA equimolar production, is measured in fluorimetry (excitation at 525 nm, emission at 549 nm). The results are expressed in fluorescence units, according to a standard range of MDA-TBA and then expressed in concentration of the MDA-TBA complex. Then, the percentage of the MDA / Linoleic starting acid (AL) ratio is determined. Then the percentage of linoleic acid protection is determined.

E) Determination of the minimum inhibitory concentration (MIC):

This test is used to determine the antibacterial activity of a compound.

Tests were carried out with 4 strains of bacteria using the principle of microdilution. MICs are determined by micromethod in a liquid medium. Successive dilutions of reason 2 of the test products in the culture broth (Trypcase Soy) are carried out in 96-well microplates in a final volume of 0.1 ml. The wells are inoculated with 0.01 ml of the bacterial suspensions titrated at approximately 10 μ CFU / ml. The microplates are incubated under optimal growth conditions and the MIC is read visually.

2) Results: A) Determination of the depigmenting activity on acellular in vitro test: test of tyrosinase inhibition.

All the results have been grouped in the Table 1 summary inserted below. - Legend of the results for the tyrosinase test

B) Assay of the melanin assay in B16-F10 cells:

The results have also been summarized in the Table 1 summary below.

- Results interpretation :

It is found that the majority of compounds tested have a good capacity for inhibition of melanin synthesis. The invention therefore relates to the cosmetic use for depigmentation of the skin of compounds of general formula (I) or

(T).

C) Test for the study of antioxidant capacity by chemiluminiscence (Photochem analytic Jena)

The results have also been summarized in the Table 1 summary below.

The majority of compounds have good antioxidant activity. The scale for interpreting the results is as follows:

Most of the compounds show results comparable to vitamin C. All the compounds show results of less than 1000 μg of trolox (30 μg being the lowest result obtained with resorcinol sulfone); they all have an interesting antioxidant activity. The invention also relates to the cosmetic use for the prevention and / or treatment of aging of the skin of the compounds of general formula (I) or (F).

D) Linoleic acid protection test following UV stress

The results have also been summarized in the Table 1 summary below. The negative control is linoleic acid not stressed by UV radiation and chemically: therefore not irradiated (NI). It is representative of the basal oxidation linked to the environment. It corresponds to the non-specific basal production of MDA, and is very low (of the order of 7 10E-7M).

The positive control is quercetin which has almost total protection at 1% and which partially protects (approximately 50%) to 0.1%.

The dose of product is expressed in weight / weight ratio, that is to say as a percentage by weight relative to the initial total amount of linoleic acid. The maximum level of MDA is determined by the UV + H202 + iron II (F) condition.

The percentage of linoleic acid protection represents: the ratio% of MDA under maximum stress untreated on% of MDA under stress conditions treated by the product.

A molecule is considered significantly active if its percentage of protection of linoleic acid is greater than 20%. The set of molecules tested is therefore significantly active. Table 1

E) Determination of the minimum inhibitory concentration (MIC):

The results are summarized in Table 2. A compound is considered to have very good antibacterial activity when it has a MIC below 1 ppm. The antibacterial activity is considered good when the MIC is between 1 ppm and 100 ppm. The antibacterial activity of a compound is considered average when it is between 100 ppm and 1000 ppm.

Table (2)

The tested compounds show significant antibacterial activity. In particular, Examples 7 and 12 exhibit strong antibacterial activity against the strain Propionibacterium acnes.

III. Composition according to the invention.

In such a composition, the percentage of active ingredient may vary between 0.01% and 10% by weight and preferably from 0.1% to 5% by weight relative to the total weight of the composition.

The invention also relates to pharmaceutical or cosmetic compositions comprising at least one of the compounds of formula (I) or of formula (T) in combination with at least one pharmaceutically or cosmetically acceptable excipient

According to a particular embodiment of the invention, the pharmaceutical or cosmetic compositions comprise at least one of the compounds of formula (I) or of formula (T) in combination with at least one pharmaceutically or cosmetically acceptable excipient and a fatty phase.

According to a particular embodiment of the invention, the pharmaceutical or cosmetic compositions comprise at least one of the compounds of formula (I) or of formula (T) in combination with at least one pharmaceutically or cosmetically acceptable excipient and an emollient.

The present invention relates to a cosmetic depigmenting composition of the skin and / or hair and / or hair characterized in that it comprises at least one compound of formula (I) or formula (F). The invention also relates to an anti-aging cosmetic composition of the skin, characterized in that it comprises at least one compound of formula (I) or of formula (V).

The invention also extends to a disinfecting pharmaceutical composition of the skin characterized in that it comprises at least one compound of formula (I).

The composition according to the invention may furthermore comprise conventional cosmetic adjuvants, chosen in particular from fatty phases, organic solvents, thickeners, softeners, opacifiers, stabilizers, emollients, anti-foam agents, moisturizing agents, perfumes, preservatives such as parabens, polymers, fillers, sequestering agents, bactericides, odor absorbers, alkalizing or acidifying agents, surfactants, free radicals, antioxidants, vitamins E and C α-hydroxy acids, or thermal waters such as Avène thermal water or any other ingredient usually used in cosmetics, in particular for the manufacture of such compositions. The composition according to the invention may further comprise a fatty phase. The fatty phase may consist of an oil or a wax or mixtures thereof, and also include fatty acids, fatty alcohols and fatty acid esters. The oils may be chosen from animal, vegetable, mineral or synthetic oils and especially from liquid petroleum jelly, liquid paraffin, silicone oils, which may or may not be volatile, such as dimethicone; isoparaffins, polyolefins, fluorinated and perfluorinated oils. Similarly, the waxes can be chosen from animal, fossil, vegetable or synthetic waxes such as beeswaxes, candelilla waxes, canauba waxes, shea butter, petroleum wax (or wax microcrystalline), paraffin, and mixtures thereof. The composition according to the invention may also comprise a polyol which is miscible with water at room temperature (approximately 25 ° C.), in particular chosen from polyols having in particular from 2 to 20 carbon atoms, preferably having from 2 to 10 carbon atoms. carbon atoms, and preferably having from 2 to 6 carbon atoms, such as glycerine; glycol derivatives such as propylene glycol, butylene glycol, pentylene glycol, hexylene glycol, dipropylene glycol, diethylene glycol; glycol ethers such as C 1 -C 4 alkyl ethers of mono-, di- or tri-propylene glycol, C 1 -C 4 alkyl ethers of mono-, di- or tri-ethylene glycol; and their mixtures. The composition according to the invention may also comprise thickening agents or rheology modifying agents, such as, for example, hydrophobically modified ethoxylated nonionic urethanes, thickening polycarboxylic acids such as acrylate / steareth-methacrylate copolymers, carbomers, crosslinked acrylate copolymers and mixtures thereof.

The composition according to the invention may also comprise acids and bases for adjusting the pH zone of said composition. The bases may be mineral (soda, potassium hydroxide, ammonia, etc.) or organic such as mono-, di- or tri-ethanolamine, aminomethylpropanediol, N-methylglucamine, basic amino acids such as arginine and lysine, and mixtures thereof.

The composition according to the invention may also comprise skin conditioning agents. Examples of skin conditioners include, but are not limited to, anionic, cationic, and nonionic emulsifiers such as sodium lauryl sulfate, sodium dioctyl sulfosuccinate, sodium stearate, sodium ester, and the like. sorbitan; ethoxylated fatty acids; ethoxylated fatty alcohols such as trideceth-9 and PEG-5 ethylhexanoate; stearic acid; any other emulsifier and conditioning agent known to those skilled in the art; and their mixtures.

The composition according to the invention may further contain other active ingredients leading to a complementary effect.

The composition according to the invention may be presented in any form suitable for topical application, in particular on the skin and / or the hair. In particular, they may be in the form of emulsions obtained by the dispersion of a fatty phase in an aqueous phase, for example an oil-in-water or water-in-oil or multiple emulsion, or in the form of a gel or an anhydrous product liquid, pasty or solid, or in the form of a dispersion in the presence of spherules. The composition according to the invention may also be less fluid and be in the form of a white or colored cream, an ointment, a milk, a lotion, a serum, a paste, a mask, a powder, a solid stick, or possibly an aerosol, a foam or a spray.

Claims

claims

1. Compound of general formula (I)

(i) wherein: X = S, SO or SO ₂ and; one of the radicals R 1 and R ₂ represents a hydrogen atom and the other a linear or branched C 1 to C 18 alkyl radical optionally substituted with one or more halogen atoms,

linear or branched C ₂ to C ₁₈ alkenyl, optionally substituted with one or more halogen atoms,

an aralkyl, optionally substituted by one or more C ₁ -C ₆ alkoxy group (s), or

»Linear alkyl branched C ₁ to C ₁₈ optionally substituted with one or more halogen atom (s),

C ₁ to C ₁₈ branched or branched alkyl, optionally substituted with one or more halogen atoms, is alkyl, optionally substituted with one or more C ₁ -C ₆ alkoxy groups; an aralkenyl, optionally substituted by one or more C ₁ -C ₆ alkoxy groups and / or one or more OH groups, or an aryl radical substituted by one or more groups; (s) C _1-6 alkoxy.

2. Compound according to claim 1, characterized in that X = S.

3. Compound according to one of claims 1 to 2, characterized in that X = S and R ₂ = H.

4. Compound according to one of claims 1 to 3, characterized in that X = S, R ₂ = H and R 1 is chosen from the group consisting of linear or branched C 1 to C ₁₈ alkyl, linear alkenyl or branched alkenyl. C ₂ to C 11 and COR ₃ or CONHR ₃ as defined in claim 1.

5. A compound according to one of claims 1 to 4, characterized in that R represents: - a linear or branched Ci to Cs and especially C 4 -C _8; or

a linear or branched C ₂ -C 18 alkenyl selected from an allyl group or a 3,3-dimethylallyl group or a geranyl group or a farnesyl group; or

a benzyl

6. Compound according to one of claims 1 to 4, characterized in that R3 represents:

linear or branched C ₇ to C 15 and in particular C ₁ to C 15 alkyl; or

linear or branched C ₁₀ -C ₁₈ alkenyl; or . benzyl; or

- a phenyl

7. Compound according to claim 1, characterized in that it is chosen from one of the following compounds: 4- (4-hydroxy-2 - ((2E, 6E) -3,6, 11-trimethyldodeca-2 , 6,10-trienyloxy) phenylthio) benzene-1,3-diol,

4- (4-hydroxy-2- (3-methylbut-2-enyloxy) phenylthio) benzene-1,3-diol, (E) -4- (2- (3,7-dimethylocta-2,6-dienyloxy)) 4-hydroxyphenylthio) benzene-1,3-diol, 4- (2-butoxy-4-hydroxyphenylthio) benzene-1,3-diol,

4- (4-butoxy-2-hydroxyphenylthio) benzene-1,3-diol, 4- (4-hydroxy-2- (octyloxy) phenylthio) benzene-1,3-diol; 4- (2-hydroxy-4- (octyloxy) phenylthio) benzene-1,3-diol, 4- (2- (benzyloxy) -4-hydroxyphenylthio) benzene-1,3-diol, 4- (4- ( benzyloxy) -2-hydroxyphenylthio) benzene-1,3-diol, 4- (4-hydroxy-2- (4-methoxybenzyloxy) phenylthio) benzene-1,3-diol, -4- (2- (decyloxy) -4- -hydroxyphénylthio) benzene-l, 3-diol,

4- (2- (hexadecyloxy) -4-hydroxyphenylthio) benzene-1,3-diol,

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl dodecanoate,

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octanoate,

4- (2,4-Dihydroxyphenylthio) -3-hydroxyphenyl-3-phenylpropanoate, 2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3-methylbutanoate, 4- (2,4-dihydroxyphenylthio) -3-hydroxyphenyl-3-methylbutanoate ,

- (9Z, 12Z) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octadeca-9, 12-dienoate

- (E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl 3- (4-methoxyphenyl) acrylate,

(E) -2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl-3- (3,4-dimethoxyphenyl) acrylate, 2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl octylcarbamate,

2- (2,4-Dihydroxyphenylsulfinyl) -5-hydroxyphenyl dodecanoate, (9Z, 12Z) -2- (2,4-dihydroxyphenylsulfinyl) -5-hydroxyphenyl octadeca-9,12-dienoate

4- (2- (decyloxy) -4-hydroxyphenylsulfmyl) benzen-1, 3-diol, 4- (2- (decyloxy) -4-hydroxyphenylsulfonyl) benzene-1,3-diol,

2- (2,4-dihydroxyphenylthio) -5-hydroxyphenyl palmitate

8. Compound of formula (T)

H

(I ') in which the radicals X, R 1 and R ₂ have identical meanings to those given in claim 1 with respect to the formula (I), but where R 1 and R ₂ may also simultaneously represent a hydrogen atom, for its use as a cosmetic active ingredient.

9. Compound of formula (V) according to claim 8 for its use as a depigmenting active ingredient.

A compound of formula (F) according to claim 8 for use as an antioxidant active ingredient.

11. Compound of formula (I) according to claims 1 to 7 for use as a medicament.

12. Compound of formula (I) according to one of claims 1 to 7 for its use as an antibacterial active ingredient.

13. Pharmaceutical or cosmetic composition, characterized in that it comprises as active ingredient at least one compound of formula (I) or formula (T) as defined according to one of claims 1 to 8 in combination with a pharmaceutically or cosmetically acceptable excipient.

14. Pharmaceutical or cosmetic composition according to claim 13, characterized in that the amount of compound of formula (I) or formula (T) varies between 0.01% and 10% by weight relative to the total weight of the composition.

15. Depigmenting cosmetic composition of the skin and / or hair and / or hair according to one of claims 13 and 14, characterized in that it comprises at least one compound of formula (I) or formula (T). ).

16. anti-aging cosmetic composition of the skin according to one of claims 13 and 14, characterized in that it comprises at least one compound of formula (I) or formula (T).

17. Disinfecting pharmaceutical composition of the skin according to one of claims 13 and 14 characterized in that it comprises at least one compound of formula (I).

18. Process for preparing a compound of general formula (I) according to one of claims 1 to 7, characterized in that 4,4'-thiodibenzene-1,3-diol or the 4,4'-sulfinylbis-1,3-benzenediol with a halide of formula II

Wherein R 1 represents a halogen atom, and R 1 has the same meaning as that given in claim 1 except for a hydrogen atom.

19. Process for the preparation according to claim 18, of a resorcinol derivative of formula (I) in which X represents SO or SO ₂ , characterized in that a compound of formula (I) in which X represents an atom is oxidized. sulfur, in particular using an aqueous solution of hydrogen peroxide.